Research
Acute Lymphoblastic Leukemia (ALL) Relapse Study
Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia
Protocol Description
The purpose of this study is to see if more intense chemotherapy used with less radiation therapy can bring about a remission in patients who have experienced a relapse from acute lymphoblastic leukemia (ALL). Treatment within this 6-phase study will include intense reception of anti-cancer drugs that have been shown to work in fighting cancer while causing less long-term side effects.
Eligibility Criteria
Patients who have been diagnosed with ALL and have had a relapse will be asked to participate.
Males: 18 months to 29 years
Females: 18 months to 29 years
Requirements
Participants will undergo an intense chemotherapy regimen throughout a 2-year period, with drug treatment administered in various methods. Additional medical procedures will be required throughout the length of the study including bone marrow aspirates, blood draws, spinal taps, and organ function tests.
Visits: Weekly
Duration: 2 years
Status: Open for Enrollment
Source of Support
Children’s Oncology Group
National Cancer Institute
Additional Resources
Children’s Oncology Group CureSearch
Study Description at National Institutes of Health
Primary Investigator(s)
A. Kim Ritchey, MD
Contact Information
To get started, please contact:
A. Kim Ritchey, MD
412-692-5055
